Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase Cβ.

Publication Type:

Journal Article

Source:

Nat Commun (2026)

Abstract:

<p>Protein kinase C (PKC) isozymes are ubiquitous kinases that direct diverse cellular pathways and are important drug targets for the treatment of cancer and neurological diseases. PKCs are auto-regulating enzymes governed by phospholipid and Ca signals via a mechanism that has remained enigmatic due to a paucity of structural information. Herein we present a series of structures of the full-length human PKCβI and PKCβII isozymes. These structures reveal the molecular basis by which PKCs maintain an auto-inhibited state, convert to a defined and ordered active conformation via a &quot;lipid-lever&quot; mechanism of allosteric activation, and how isoform-specific differences alter their allosteric regulatory mechanisms. We show that endoxifen, a recently identified PKCβI inhibitor, can alter the allosteric regulatory mechanism of PKCβI, providing a proof of concept for allosteric regulators of PKCs. Collectively, our data describe a foundational molecular model of second messenger-mediated allosteric regulation of PKCs that underpins PKC function, misregulation, and mechanisms of inhibition.</p>

PDB: 
8SE1, 8SE2, 8SE3, 8SE4
Detector: 
EIGER
EIGER2
Beamline: 
24-ID-C
24-ID-E